Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
or

Akero Therapeutics Inc (AKRO)

Akero Therapeutics Inc (AKRO)
48.46 x 1 54.00 x 1
Post-market by (Cboe BZX)
49.44 -1.08 (-2.14%) 02/18/25 [NASDAQ]
48.46 x 1 54.00 x 1
Post-market 51.00 +1.56 (+3.16%) 16:46 ET
Quote Overview for Tue, Feb 18th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
49.35
Day High
51.39
Open 51.39
Previous Close 50.52 50.52
Volume 995,700 995,700
Avg Vol 2,196,855 2,196,855
Stochastic %K 17.26% 17.26%
Weighted Alpha +12.29 +12.29
5-Day Change -1.71 (-3.34%) -1.71 (-3.34%)
52-Week Range 17.86 - 58.40 17.86 - 58.40
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,526,246
  • Shares Outstanding, K 69,799
  • Annual Sales, $ 0 K
  • Annual Income, $ -151,760 K
  • EBIT $ -269 M
  • EBITDA $ -278 M
  • 60-Month Beta -0.11
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 4.63

Options Overview Details

View History
  • Implied Volatility 57.96% ( -0.69%)
  • Historical Volatility 203.08%
  • IV Percentile 20%
  • IV Rank 11.73%
  • IV High 293.20% on 01/16/25
  • IV Low 26.69% on 08/16/24
  • Put/Call Vol Ratio 0.45
  • Today's Volume 642
  • Volume Avg (30-Day) 1,800
  • Put/Call OI Ratio 1.30
  • Today's Open Interest 34,311
  • Open Int (30-Day) 27,571

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -1.14
  • Number of Estimates 5
  • High Estimate -1.08
  • Low Estimate -1.20
  • Prior Year -0.99
  • Growth Rate Est. (year over year) -15.15%

Price Performance

See More
Period Period Low Period High Performance
1-Month
24.69 +100.24%
on 01/23/25
Period Open: 25.14
58.40 -15.34%
on 01/27/25
+24.30 (+96.66%)
since 01/17/25
3-Month
21.34 +131.68%
on 01/14/25
Period Open: 29.56
58.40 -15.34%
on 01/27/25
+19.88 (+67.25%)
since 11/18/24
52-Week
17.86 +176.82%
on 06/05/24
Period Open: 20.89
58.40 -15.34%
on 01/27/25
+28.55 (+136.67%)
since 02/16/24

Most Recent Stories

More News
This Stock Just Doubled in 1 Day -- Is It Still a Buy?

We are still pretty early in the new year, but some companies are already delivering outsize returns to their shareholders. Akero Therapeutics (NASDAQ: AKRO) is part of this group. On Jan. 27, the company's...

AKRO : 49.44 (-2.14%)
Akero Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares

AKRO : 49.44 (-2.14%)
Akero Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants

AKRO : 49.44 (-2.14%)
Technology Stocks Upended by China’s DeepSeek

The S&P 500 Index ($SPX ) (SPY ) Monday closed down -1.46%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.65%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -2.97%. March E-mini...

MSTR : 333.97 (-1.11%)
JNJ : 154.99 (+0.05%)
KHC : 29.32 (+1.38%)
COIN : 264.63 (-3.53%)
AMD : 114.28 (+1.04%)
SPY : 611.49 (+0.29%)
PTLO : 15.14 (+0.40%)
HCA : 316.71 (+0.16%)
MU : 106.79 (+7.31%)
CAG : 23.90 (-5.46%)
AMT : 189.55 (+0.09%)
ORCL : 179.80 (+3.24%)
Akero Therapeutics Announces Proposed Public Offering of Common Stock

AKRO : 49.44 (-2.14%)
Stocks Hit by AI Jitters

The S&P 500 Index ($SPX ) (SPY ) today is down -1.64%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.10%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -2.68%. March E-mini S&P futures...

MSTR : 333.97 (-1.11%)
AMAT : 172.00 (+1.65%)
CVS : 65.57 (-0.39%)
AVGO : 228.53 (-1.94%)
KHC : 29.32 (+1.38%)
JNJ : 154.99 (+0.05%)
$IUXX : 22,164.61 (+0.23%)
COIN : 264.63 (-3.53%)
UNH : 500.73 (-4.35%)
ASML : 744.22 (-0.98%)
ZNH25 : 108-265 (-0.01%)
ESH25 : 6,152.75 (+0.10%)
Stocks Slump as China’s DeepSeek Rattles Tech Stocks

The S&P 500 Index ($SPX ) (SPY ) today is down -1.63%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.35%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -2.66%. March E-mini S&P futures...

MSTR : 333.97 (-1.11%)
AMAT : 172.00 (+1.65%)
GOOGL : 183.77 (-0.79%)
AVGO : 228.53 (-1.94%)
KHC : 29.32 (+1.38%)
JNJ : 154.99 (+0.05%)
$IUXX : 22,164.61 (+0.23%)
COIN : 264.63 (-3.53%)
UNH : 500.73 (-4.35%)
ASML : 744.22 (-0.98%)
ZNH25 : 108-265 (-0.01%)
MSFT : 409.64 (+0.30%)
Akero Stock Hits Over 18-Month High On MASH Trial Data: Citi Lauds ‘Best-Case Scenario,’ Retail Exuberant

The analyst highlighted that major pharmaceutical companies are already pursuing GLP-1-based therapies for MASH, but he believes efruxifermin could complement these treatments.

IWN : 168.17 (+0.41%)
AKRO : 49.44 (-2.14%)
XBI : 91.33 (-0.09%)
Akero Therapeutics Reports Preliminary Topline Results Showing Statistically Significant Reversal of Compensated Cirrhosis (F4) Due to MASH—by Both Completer and ITT Analyses—at Week 96 in Phase 2b SYMMETRY Study

AKRO : 49.44 (-2.14%)
Akero Therapeutics to Present Preliminary Topline Week 96 Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASH

AKRO : 49.44 (-2.14%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Akero Therapeutics Inc. is a clinical-stage biotechnology company. It is focused on developing transformational treatments for non-alcoholic steatohepatitis and other serious metabolic disorders. The company's product pipeline consists of AKR-001, for the treatment of non-alcoholic steatohepatitis, which...

See More

Key Turning Points

3rd Resistance Point 52.82
2nd Resistance Point 52.10
1st Resistance Point 50.77
Last Price 49.44
1st Support Level 48.73
2nd Support Level 48.01
3rd Support Level 46.68

See More

52-Week High 58.40
Last Price 49.44
Fibonacci 61.8% 42.91
Fibonacci 50% 38.13
Fibonacci 38.2% 33.35
52-Week Low 17.86

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

Increase Profitable Opportunities with Barchart's Technical Opinion